Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $34.85 | Total: $174.25 |
| 1 | 10 | $29.52 | Total: $295.20 |
| 1 | 25 | $25.01 | Total: $625.25 |
| 1 | 50 | $21.32 | Total: $1,066.00 |
| 1 | 100 | $18.45 | Total: $1,845.00 |
Overview
LY2857785 is a type I competitive and reversible ATP kinase inhibitor against CDK7CDK8CDK9 (IC50s: 246 nM16 nM11 nM).
Chemical Properties
| Molecular Formula | C26H36N6O |
| Molecular Weight | 448.6 |
| CAS Numbers | 1619903-54-6 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Yin T, et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther. 2014 Jun;13[6] 1442-56. Mol Cancer Ther. 2014 Jun;13[6] 1442-56.